Cathie Wood's Gambit: Are Her New High-Risk Bets the Key to Your Portfolio's Future?

Cathie Wood of ARK Invest Goes Bargain Hunting: Should These Picks Be in Your Portfolio?

If anyone knows how to generate buzz—and sometimes controversy—it's Cathie Wood, the co-founder, CEO, and investment manager of ARK Invest. Renowned for her daring growth stock picks, Wood’s strategies often become hot topics in the trading community. Recently, Wood has made some intriguing moves by upping her stakes in three companies: Adaptive Biotechnologies (NASDAQ: ADPT), Intellia Therapeutics (NASDAQ: NTLA), and Shopify (NYSE: SHOP). With these stocks experiencing significant declines in 2024, traders are left wondering if these are savvy investments or risky gambles.

Shopify: An E-Commerce Titan on Sale

Shopify (NYSE: SHOP) has been a cornerstone of Wood’s ARK portfolios, particularly during her stellar performance in 2020. Despite this, 2024 hasn't been as kind, with shares tumbling 27% from their peak. A recent earnings report didn't meet market expectations, causing the stock to dip a staggering 19%, although revenue did increase by 23% (29% if you exclude the divested logistics sector).

The reality is that Shopify continues to broaden its market presence and maintain strong free cash flow margins. Analysts are predicting revenue growth rates of 21% this year and around 20% in 2025, coupled with notable profitability increases. Both Wood and investment giant Goldman Sachs argue that the market has exaggerated Shopify’s decline, viewing the current drop as a buying opportunity.

Intellia Therapeutics: Gene-Editing Pioneer Facing Growing Pains

Intellia Therapeutics (NASDAQ: NTLA), known for its cutting-edge CRISPR technology, has also caught Wood's eye. Despite beating earnings estimates, the stock saw a 16% decline year-to-date. Intellia is making significant strides, with one of its gene-editing treatments in the third phase of clinical trials and another nearing that critical juncture.

Boasting substantial cash reserves, the company has the financial cushion to continue its ambitious R&D endeavors. Wood’s decision to increase her stake reflects her confidence in the long-term potential of gene-editing technologies. As of the latest filing, ARK holds a hefty $49,253 worth of Intellia shares.

Adaptive Biotechnologies: Betting on Genetic Sequencing

Lastly, there's Adaptive Biotechnologies (NASDAQ: ADPT), another key player in Wood's latest investment spree. Although the stock has plummeted 50% this year, the company has reported positive financial results, including an upbeat forecast for its minimal residual disease (MRD) business and narrower losses. However, the recent departure of the CFO has marred investor sentiment.

Still, Wood remains bullish on Adaptive’s future, and ARK’s portfolio now includes a more significant portion of its stock—over 7%. Her investment signals a strong belief in the future of genetic sequencing technology, a sector showing tremendous promise despite current market challenges.

For the astute trader, Cathie Wood’s picks offer high-risk, high-reward scenarios. Those willing to weather the volatility might find substantial gains in the long term. As always, the golden rule remains: diversify to mitigate risk.